Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Datamonitor Healthcare Reports | Bausch and Lomb's Contact Lens Solution Withdrawal - ReNu MultiPlus likely to struggle in attempt to regain market share

Bausch and Lomb's Contact Lens Solution Withdrawal - ReNu MultiPlus likely to struggle in attempt to regain market share

In May 2006 Bausch & Lomb's ReNu with MoistureLoc contact lens solution was permanently withdrawn from markets worldwide due to an outbreak of a fungal eye infection. For a large market player, the loss of a new revenue driver and the negative publicity surrounding the event is likely to have a significant impact on future success, as well as implications for other companies in the sector.

Scope

> This report analyzes the market outlook in the aftermath of the withdrawal of Bausch & Lomb's ReNu with MoistureLoc contact lens solution

> Datamonitor interviewed eight optometrists from the US and the EU in the course of research

Highlights

> Bausch & Lomb's explanation of the cause of infection is in line with suspicions of interviewed optometry experts that the revolutionary make-up of MoistureLoc's formula made it susceptible to external factors that could elevate infection risk.

> Moving forward, US practitioners will likely put more emphasis on patient adherence to particular recommended brands, and patients are likely to be less price-sensitive, favoring competitors over Bausch & Lomb's older contact lens solution, ReNu MultiPlus.

> Collateral damage to Bausch & Lomb's eye care franchise in European markets is expected to be minimal.

Reasons to Purchase

> Understand the implications of Bausch & Lomb's product recall through in-depth analysis based on interviews with leading experts

> Anticipate likely changes in the future market dynamics for contact lens solutions following the withdrawal of ReNu with MoistureLoc

29-Aug-06 PDF 12
Table of Contents
Price: $3,800.00 / €2,542.20

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions